Document Detail

Update in inclusion body myositis.
MedLine Citation:
PMID:  24067381     Owner:  NLM     Status:  In-Data-Review    
PURPOSE OF REVIEW: The purpose of this study is to review recent scientific advances relating to the natural history, cause, treatment and serum and imaging biomarkers of inclusion body myositis (IBM).
RECENT FINDINGS: Several theories regarding the aetiopathogenesis of IBM are being explored and new therapeutic approaches are being investigated. New diagnostic criteria have been proposed, reflecting the knowledge that the diagnostic pathological findings may be absent in patients with clinically typical IBM. The role of MRI in IBM is expanding and knowledge about pathological biomarkers is increasing. The recent description of autoantibodies to cytosolic 5' nucleotidase 1A in patients with IBM is a potentially important advance that may aid early diagnosis and provides new evidence regarding the role of autoimmunity in IBM.
SUMMARY: IBM remains an enigmatic and often misdiagnosed disease. The pathogenesis of the disease is still not fully understood. To date, pharmacological treatment trials have failed to show clear efficacy. Future research should continue to focus on improving understanding of the pathophysiological mechanisms of the disease and on the identification of reliable and sensitive outcome measures for clinical trials. IBM is a rare disease and international multicentre collaboration for trials is important to translate research advances into improved patient outcomes.
Pedro Machado; Stefen Brady; Michael G Hanna
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current opinion in rheumatology     Volume:  25     ISSN:  1531-6963     ISO Abbreviation:  Curr Opin Rheumatol     Publication Date:  2013 Nov 
Date Detail:
Created Date:  2013-09-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9000851     Medline TA:  Curr Opin Rheumatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  763-71     Citation Subset:  IM    
MRC Centre for Neuromuscular Diseases, Institute of Neurology, University College London, London, UK *Pedro Machado and Stefen Brady have contributed equally to this article.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Biomarkers of inclusion body myositis.
Next Document:  IL-6 Regulates Neutrophil Microabscess Formation in IL-17A-Driven Psoriasiform Lesions.